1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novartis AG

Novartis AG

NVSEF
Novartis AGUS flagOther OTC
144.14
USD
- -
- -
275.03BMarket Cap
Novartis AG
NVSEF
(Other OTC)

Recent

price

144.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
22.56
24.93
21.49
21.6
22.11
20.97
20.79
18.5
19.88
21.25
21.91
19.6
19.93
22.47
25.63
29.23
29.42
Revenue per Share
4.28
3.75
3.83
3.76
4.21
7.4
2.82
3.28
5.44
5.12
3.55
10.71
3.19
7.15
5.92
7.21
7.04
Basic EPS, GAAP
5.18
5.01
4.72
4.01
4.33
3.49
3.61
4.4
5.01
4.96
4.86
5.58
5.5
5.64
6.84
7.86
8.3
Free Cash Flow per Basic Share
1.96
2.25
2.49
2.5
2.81
2.76
2.72
2.77
3
2.9
3.07
3.28
3.44
3.49
3.78
4.03
4.51
Dividend per Share
27.7
27.69
0.41
30.34
30.27
33.86
34.53
33.51
35.85
26.28
25.5
32.05
29.54
24.3
23.47
0.4
19.75
Book Value per Share
2.12
1.69
3.24
6.39
7.3
4.88
5.29
5.32
2.02
0.1
-4.45
1.8
-0.7
-1.67
-3.74
-4.35
-14.61
Tangible Book Value per Share
2,286
2,382
2,418
2,441
2,426
2,403
2,378
2,346
2,319
2,291
2,277
2,243
2,181
2,077
2,018
1,939
1,923
Basic Weighted Avg Shares
51,561
59,375
51,971
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
56,578
Sales/Revenue/Turnover
22.35
18.16
22.14
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.43
Operating Margin (%)
3,419
5,788
4,442
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
5,399
Depreciation Expense
9,794
8,940
9,270
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
13,534
Net Income, GAAP
14.81
14.05
15.18
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
14.38
Effective Tax Rate (%)
18.99
15.06
17.84
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
23.92
Profit Margin (%)
2,027
936
3,953
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-4,767
Working Capital
14,360
13,855
13,781
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
39,110
LT Debt
69,769
65,940
69,263
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
38,927
Total Equity
11.43
9.94
10.76
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
18.42
Return on Invested Capital (%)
12.42
10.56
18.24
17.08
11.57
18.61
7.01
7.81
12.1
12.12
9.47
24.87
7.8
18.48
16.48
25.99
18.55
Return on Capital (%)
16.21
13.83
27.69
24.44
13.84
22.97
8.21
9.59
15.59
16.37
13.65
36.97
10.2
25.85
24.41
58.12
34.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7,784
5,784
7,888
LT Borrowings
22,598
27,935
37,447
LT Finance Leases
1,640
1,657
1,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,919
1,908
1,908
Market Capitalization
243,105
268,134
279,845

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,198
30,460
26,607
Cash, Cash Equivalents & STI
9,753
11,533
6,977
Accounts Receivable, Net
8,844
8,937
9,386
Inventories
6,421
6,269
6,286
Total Current Liabilities
32,000
27,278
31,374
Payables & Accruals
7,897
9,517
6,129
ST Debt
7,784
5,784
7,888
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.32
1.6
1.58
1.42
5.92
2025
1.83
2.07
- -
1.26
7.21
2026
1.65
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.55
1.19
- -
- -
3.78
2025
2.71
1.28
- -
- -
4.03
2026
3.25
- -
- -
- -
- -
Similar Companies
Dimed S.A. Distribuidora de Medicamentos (PNVL3.SA)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
Bayer AG (BAYN.SG)
NGL Fine-Chem Limited (NGLFINE.NS)
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (600613.SS)
Business
Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel that focuses on the research, development, manufacturing, and marketing of innovative medicines for patients with serious diseases across oncology, immunology, neuroscience, cardiovascular, renal, metabolic, and other therapeutic areas. The company offers a broad portfolio of branded pharmaceuticals including Kisqali (ribociclib) for breast cancer; Entresto (sacubitril/valsartan) for heart failure; Cosentyx (secukinumab) for inflammatory conditions such as psoriasis; Scemblix (asciminib) and Tasigna (nilotinib) for chronic myeloid leukemia; Pluvicto for prostate cancer; Fabhalta (iptacopan) for rare kidney diseases including C3G and IgA nephropathy; Sandostatin (octreotide) and Signifor (pasireotide) for acromegaly and Cushing's disease; Gilenya (fingolimod) and Mayzent (siponimod) for multiple sclerosis; Diovan (valsartan) and Exforge (amlodipine/valsartan) for hypertension; Lucentis (ranibizumab) for eye diseases; Gleevec (imatinib) for oncology; Kymriah (tisagenlecleucel), a CAR-T cell therapy for blood cancers; and radioligand therapies, cell and gene therapies, as well as treatments for infectious diseases like malaria and influenza; it operates globally with a presence in over 100 countries, supported by R&D hubs in Basel, Cambridge, and San Diego. Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis spun off its generics business Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on innovative medicines. Recent developments include the October 2025 agreement to acquire Avidity Biosciences for approximately $12 billion to enhance RNA therapeutics for neuromuscular diseases; April 2025 plans for a $23 billion US manufacturing and R&D expansion across 10 facilities including a new radioligand therapy plant in California and a $1.1 billion San Diego research hub; 2025 acquisitions of Anthos Therapeutics and Regulus Therapeutics; partnerships and licensing deals exceeding $17 billion such as with Argo Biopharma for siRNA candidates, Dren Bio for bispecific antibodies, and Ratio Therapeutics for radiotherapeutics; new approvals for Pluvicto in pre-taxane prostate cancer, Vanrafia for IgA nephropathy, and Fabhalta for C3G; and projections for 5-6% compound annual sales growth through 2029-2030 bolstered by these pipeline advancements.

Company News

APIChat

  • globenewswire.com

    New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer